<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21584060</article-id><article-id pub-id-type="pmc">2967098</article-id><article-id pub-id-type="publisher-id">IJPsy-39-136</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>TREATMENT OF ACUTE AND TRANSIENT PSYCHOTIC DISORDERS WITH LOW AND HIGH DOSES OF ORAL HALOPERIDOL</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khanna</surname><given-names>Apurv</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lal</surname><given-names>Narottam</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Dalal</surname><given-names>P.K.</given-names></name><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Khalid</surname><given-names>Abdul</given-names></name><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Trivedi</surname><given-names>J.K.</given-names></name><xref ref-type="aff" rid="aff5"/><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1">APURV KHANNA, M.B.B.S., Ex-Resident, Department of Psychiatry, K.G. Medical College, Lucknow-226003.</aff><aff id="aff2">NAROTTAM LAL, M.D., Professor, Department of Psychiatry, K.G. Medical College, Lucknow-226003.</aff><aff id="aff3">P.K. DALAL, M.D., Associate Professor, Department of Psychiatry, K.G. Medical College, Lucknow-226003.</aff><aff id="aff4">ABDUL KHALID, M.D., Senior Resident, Department of Psychiatry, K.G. Medical College, Lucknow-226003.</aff><aff id="aff5"><label>*</label>J.K. TRIVEDI, M.D., Professor, Department of Psychiatry, K.G. Medical College, Lucknow-226003.</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence</bold></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>1997</year></pub-date><volume>39</volume><issue>2</issue><fpage>136</fpage><lpage>142</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>1997</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The apparent rationale for the popular use of high doses of neuroleptics in psychotic patients is to increase the degree and speed of therapeutic response .However, several recent reports have questioned these claims. The present study was undertaken with the aim to compare the efficacy of high and low oral doses of haloperidol in the treatment of acute and transient psychotic disorders. The sample comprised of forty patients of both sexes diagnosed as acute and transient psychotic disorder who were randomly assigned to high dose (20 mg/day) and low dose (5 mg /day) haloperidol groups with equal number of subjects (n=20) in both groups. Weekly assessment was done on Brief Psychiatric Rating Scale and Haloperidol Side-effects Check List (day 7, 14, 21, 28, 35 &#x00026; 42). Both groups showed significant improvement in BPRS from baseline scores on all assessments. Comparison of the improvement rate in both study groups revealed no significant difference.</p></abstract><kwd-group><kwd>Oral haloperidol</kwd><kwd>low dose</kwd><kwd>high dose</kwd><kwd>acute and transient psychotic disorders</kwd></kwd-group></article-meta></front></article>